188 related articles for article (PubMed ID: 15774773)
1. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
Schrag D; Weiser M; Schattner M; Shia J; Akhurst T
J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773
[No Abstract] [Full Text] [Related]
2. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
[TBL] [Abstract][Full Text] [Related]
3. Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
Chua TC; Marshall JL; Marshall MB; Esquivel J
Am Surg; 2010 Jul; 76(7):777-8. PubMed ID: 20698392
[No Abstract] [Full Text] [Related]
4. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version.
Zalinski S; Mariette C; Farges O; ; ;
J Visc Surg; 2011 Jun; 148(3):e171-82. PubMed ID: 21703959
[No Abstract] [Full Text] [Related]
5. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
6. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
[No Abstract] [Full Text] [Related]
7. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
8. A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
Catania C; Pelosi G; Fazio N; Biffi R; Spitaleri G; Noberasco C; Zampino MG; Maggioni A; Trifirò G; Toffalorio F; Vigna PD; De Braud F; De Pas T
Acta Oncol; 2010; 49(1):120-1. PubMed ID: 20100147
[No Abstract] [Full Text] [Related]
9. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
10. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
[No Abstract] [Full Text] [Related]
11. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A;
Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184
[TBL] [Abstract][Full Text] [Related]
12. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Kawakami H; Satoh T; Nakagawa K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
[No Abstract] [Full Text] [Related]
13. Pathologic complete response after FOLFOX7 in a locally advanced rectal cancer.
Li J; Rose MG; Perkal MF; Chao HH
J Clin Gastroenterol; 2012 Jan; 46(1):87-8. PubMed ID: 22157222
[No Abstract] [Full Text] [Related]
14. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Hecht JR; Trarbach T; Hainsworth JD; Major P; Jäger E; Wolff RA; Lloyd-Salvant K; Bodoky G; Pendergrass K; Berg W; Chen BL; Jalava T; Meinhardt G; Laurent D; Lebwohl D; Kerr D
J Clin Oncol; 2011 May; 29(15):1997-2003. PubMed ID: 21464406
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Beretta GD; Scartozzi M; Tondulli L; Cascinu S
J Clin Oncol; 2010 Jun; 28(16):e268-9; author reply e270. PubMed ID: 20385975
[No Abstract] [Full Text] [Related]
17. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
[TBL] [Abstract][Full Text] [Related]
18. [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
Matoba S; Sawada T; Toda S; Moriyama J; Yokoyama T; Ehara K; Mine S; Ueno M; Kinoshita Y; Matsuda M; Tsutsumi K; Hashimoto M; Udagawa H; Watanabe G; Katori H; Hayashi M; Igarashi M; Ito T; Hasebe S; Sato M
Gan To Kagaku Ryoho; 2008 Apr; 35(4):673-5. PubMed ID: 18408443
[TBL] [Abstract][Full Text] [Related]
19. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
20. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Mishima H; Ikenaga M; Yasui M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
